<DOC>
	<DOCNO>NCT01847651</DOCNO>
	<brief_summary>Patients cirrhosis liver may suffer condition call hepatic encephalopathy mild form mental slow impaired reaction time drive machinery operation . Left untreated may lead deep coma . The cause fully understood though related inability damage liver filter toxin ammonia blood , accumulate within brain result alter function swell within certain brain cell , astrocyte . These patient also suffer muscle loss , associate poor outcome . L-ornithine L-aspartate ( LOLA ) license drug Germany show promote ammonia elimination body form urea . Some experimental study suggest LOLA also potentially attenuate muscle loss incorporate ammonia muscle form glutamine . The aim study determine cognitive nutritional effect 12 week LOLA administration effect brain muscle structure function patient cirrhosis .</brief_summary>
	<brief_title>Brain Muscle Axis During Treatment Hepatic Encephalopathy With L-ornithine L-aspartate</brief_title>
	<detailed_description>This Phase IV randomise double blind , placebo control study . Thirty four patient cirrhosis study psychometric test , clinical brain magnetic resonance imaging ( MRI ) , include functional MRI ) magnetic resonance spectroscopy ( MRS ) muscle MRI leg muscle ( time 0 ) ( 4weeks ) LOLA placebo treatment 12 week . Samples also take ex vivo MRS blood urine identify potential biomarkers . Histological analysis MRS would also perform muscle tissue time point . Hypotheses Primary objective 1 ) Improvement mental state paper pencil base Psychometric Hepatic Encephalopathy Score ( PHES ) Cogstate Research test ( computer base cognitive research assessment tool ) Secondary objectives 1 . Brain volume reduction due reduction brain swelling measure MRI improvement chemical structure brain due ( cerebral osmolytes ) measure vivo MR Spectroscopy ( MRS ) scan brain . 2 . Improvement brain function 3 . Improvement muscle function ( muscle metabolome normalisation ) increase muscle size ( fat free mass ) , measure vivo MRI scan vitro mass spectroscopy NMR spectroscopy histological analysis muscle sample . 4 . Improvement chemical profile key chemical blood urine , measure vitro NMR spectroscopy</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>N-Methylaspartate</mesh_term>
	<criteria>Ambulant patient ChildPugh stage cirrhosi PHEs define MHe grade 1 encephalopathy Previous episode overt HE without clear precipitant Recurrent excessive alcohol consumption ( abstinence alcoholic liver disease otherwise less 28 unit per week ) Severe coagulopathy ( INR &gt; 2 , platelet &lt; 60 000/uL , Fibrinogen &lt; 1mg/dl ) know myopathy myositis , taruma low extremity within 3 month ) Renal dysfunction serum creatinine &gt; 3mg/dl ( 265micromol/L ) Ferromagnetic implant Recent intestinal haemorrhage within 1 month Claustrophobia Weight &gt; 120kg Major psychoactive medication antipsychotic agent Known cerebrovascular disease preexist neurological condition Age le 18 great 65 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>hepatic encephalopathy</keyword>
	<keyword>minimal hepatic encephalopathy</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>lateral vastus</keyword>
	<keyword>muscle biopsy</keyword>
	<keyword>L ornithine L aspartate</keyword>
	<keyword>functional magnetic resonance imaging</keyword>
	<keyword>magnetic resonance spectroscopy</keyword>
	<keyword>cognitive testing</keyword>
	<keyword>Paper pencil Hepatic Encephalopathy score ( PHES )</keyword>
	<keyword>Cogstate</keyword>
	<keyword>urine metabonomics</keyword>
	<keyword>plasma metabonomics</keyword>
	<keyword>muscle metabonomics</keyword>
</DOC>